Valneva SE (0OB3.L)
0OB3.L Stock Price Chart
Explore Valneva SE interactive price chart. Choose custom timeframes to analyze 0OB3.L price movements and trends.
0OB3.L Company Profile
Discover essential business fundamentals and corporate details for Valneva SE (0OB3.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
17 Feb 2011
Employees
713.00
Website
https://valneva.comCEO
Thomas Lingelbach
Description
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
0OB3.L Financial Timeline
Browse a chronological timeline of Valneva SE corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 12 Aug 2025
EPS came in at -€0.07 surpassing the estimated -€0.14 by +48.54%, while revenue for the quarter reached €48.33M , beating expectations by +9.36%.
Earnings released on 7 May 2025
EPS came in at -€0.06 surpassing the estimated -€0.13 by +52.08%, while revenue for the quarter reached €49.20M , beating expectations by +10.60%.
Earnings released on 20 Mar 2025
EPS came in at -€0.23 falling short of the estimated -€0.09 by -152.93%, while revenue for the quarter reached €52.94M , beating expectations by +44.26%.
Earnings released on 7 Nov 2024
EPS came in at -€0.06 surpassing the estimated -€0.12 by +53.34%, while revenue for the quarter reached €45.82M , beating expectations by +1.95%.
Earnings released on 13 Aug 2024
EPS came in at -€0.19 falling short of the estimated -€0.16 by -20.50%, while revenue for the quarter reached €38.06M , missing expectations by -7.94%.
Earnings released on 7 May 2024
EPS came in at €0.42 falling short of the estimated €0.52 by -18.68%, while revenue for the quarter reached €32.75M , missing expectations by -50.83%.
Earnings released on 20 Mar 2024
EPS came in at -€0.23 falling short of the estimated €0.04 by -634.76%, while revenue for the quarter reached €41.90M , missing expectations by -41.02%.
Earnings released on 30 Sept 2023
EPS came in at -€0.25 falling short of the estimated -€0.21 by -16.48%, while revenue for the quarter reached €38.07M , missing expectations by -10.46%.
Earnings released on 30 Jun 2023
EPS came in at -€0.12 surpassing the estimated -€0.12 by +0.51%, while revenue for the quarter reached €40.24M , beating expectations by +31.26%.
Earnings released on 31 Mar 2023
EPS came in at -€0.13 surpassing the estimated -€0.18 by +25.84%, while revenue for the quarter reached €33.51M , beating expectations by +10.27%.
Earnings released on 31 Dec 2022
EPS came in at -€0.32 falling short of the estimated €0.11 by -382.01%, while revenue for the quarter reached €111.40M , missing expectations by -25.30%.
Earnings released on 30 Sept 2022
EPS came in at €0.62 surpassing the estimated €0.31 by +97.38%, while revenue for the quarter reached €156.68M , beating expectations by +34.05%.
Earnings released on 30 Jun 2022
EPS came in at -€1.34 falling short of the estimated -€0.52 by -155.86%, while revenue for the quarter reached €71.38M , beating expectations by +261.74%.
Earnings released on 31 Mar 2022
EPS came in at -€0.24 falling short of the estimated -€0.19 by -28.12%, while revenue for the quarter reached €21.85M , beating expectations by +0.14%.
Earnings released on 31 Dec 2021
EPS came in at €1.71 , while revenue for the quarter reached €278.24M .
Earnings released on 30 Sept 2021
EPS came in at -€1.60 falling short of the estimated €0.92 by -273.59%, while revenue for the quarter reached €22.35M , missing expectations by -85.35%.
Earnings released on 30 Jun 2021
EPS came in at -€0.61 , while revenue for the quarter reached €24.29M .
Earnings released on 31 Mar 2021
EPS came in at -€0.30 , while revenue for the quarter reached €23.22M .
Earnings released on 31 Dec 2020
EPS came in at -€0.02 , while revenue for the quarter reached €51.47M .
Earnings released on 30 Sept 2020
EPS came in at -€0.42 , while revenue for the quarter reached €10.94M .
0OB3.L Stock Performance
Access detailed 0OB3.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.